ARKG240705C27000
- 0.03
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company's impressive second
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Leerink Partners Initiates Coverage On Schrodinger With Outperform Rating, Announces Price Target of $29
Leerink Partners analyst Mani Foroohar initiates coverage on Schrodinger (NASDAQ:SDGR) with a Outperform rating and announces Price Target of $29.
Schrodinger Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 48.83% Leerink Partners → $29 Initiates Coverage On → Outperform 05/02/2024 89.89% Citigroup $3
HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price target.
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 157.62% HC Wainwright & Co. $60 → $60 Reiterates Buy → Buy 05/10/2024 269.26% Canaccord Genuity
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.The PLTR TradeArk Invest, through its ARK Au
Arcturus to File IND for Phase 2 Study for Cystic Fibrosis Candidate
Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this yearARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more sev
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Twist Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 24.64% Barclays $45 → $60 Maintains Overweight 06/13/2024 35.02% TD Cowen $55 → $65 Maintains B
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rece
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $26
RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $23 to $26.
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 24.02% RBC Capital $23 → $26 Maintains Outperform 06/18/2024 24.02% HC Wainwright & Co. $19 → $
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 213.71% Canaccord Genuity $73 → $73 Maintains Buy 06/24/2024 179.33% Cantor Fitzgerald $65 → $6
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Thursday after the company announced a proposed offering of its common stock.What Happened: Recursion announced that it intends to
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates th
Market-Moving News for June 27th
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40MME